(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
13h
News Medical on MSNThis New Treatment Can Adjust to Parkinson’s Symptoms in Real TimeThe FDA has approved an adaptive deep brain stimulation (aDBS) treatment for people with with Parkinson’s disease, making this groundbreaking technology available to people nationwide.
20h
GlobalData on MSNFDA approves Medtronic’s brain stimulation system for Parkinson’sThe FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results